Litigation Details for AstraZeneca Pharmaceuticals LP v. Teva Pharmaceuticals USA Inc. (D. Del. 2014)

« Back to Dashboard

AstraZeneca Pharmaceuticals LP v. Teva Pharmaceuticals USA Inc. (D. Del. 2014)

Docket		Date Filed	2014-12-12
Court	District Court, D. Delaware	Date Terminated	2016-06-27
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Parties	TEVA PHARMACEUTICAL INDUSTRIES LTD.; TEVA PHARMACEUTICALS USA INC.
Patents	6,858,576; 6,872,700; 6,902,744; 6,956,026; 7,297,761; 7,521,423; 7,741,269
Attorneys	Frederick H. Rein; Reddy K. Srikanth
Firms	Shaw Keller LLP; Shaw Keller LLP, I.M. Pei Building
Link to Docket	External link to docket

Details for AstraZeneca Pharmaceuticals LP v. Teva Pharmaceuticals USA Inc. (D. Del. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-12-12				External link to document

AstraZeneca Pharmaceuticals LP v. Teva Pharmaceuticals USA Inc. Litigation Summary, 1:14-cv-01478

Last updated: October 3, 2026

AstraZeneca Pharmaceuticals LP v. Teva Pharmaceuticals USA Inc., No. 1:14-cv-01478, was an ANDA patent case in the U.S. District Court for the District of Delaware involving AstraZeneca's dapagliflozin product Farxiga. AstraZeneca sued after Teva notified AstraZeneca that it had filed an abbreviated new drug application seeking approval for a generic version of dapagliflozin tablets. The case was part of the broader U.S. patent campaign protecting Farxiga and related dapagliflozin products.

The principal business issue was whether Teva could obtain FDA approval and launch before expiration of AstraZeneca's listed patents. The litigation did not produce a reported merits judgment invalidating the core Farxiga patent estate. The matter was resolved through a settlement and subsequent dismissal, leaving generic launch timing governed primarily by the settlement terms and the remaining Orange Book patents.

What drug and patents were involved in AstraZeneca v. Teva?

The case concerned Farxiga, the U.S. brand name for dapagliflozin tablets. Dapagliflozin is an SGLT2 inhibitor used to treat type 2 diabetes and, following later FDA approvals, heart failure and chronic kidney disease.

Product and regulatory profile

Item	Detail
Brand	Farxiga
Active ingredient	Dapagliflozin
Dosage form	Immediate-release oral tablets
Original U.S. sponsor	Bristol-Myers Squibb and AstraZeneca
Current commercial owner	AstraZeneca
FDA approval	January 2014
ANDA defendant	Teva Pharmaceuticals USA Inc.
Court	U.S. District Court for the District of Delaware
Case number	1:14-cv-01478
Case type	Hatch-Waxman patent infringement action

AstraZeneca's complaint followed a Paragraph IV certification. Teva's certification asserted that the relevant patents were invalid, unenforceable, or would not be infringed by Teva's proposed product. Filing the suit within 45 days of the Paragraph IV notice triggered the statutory 30-month stay of FDA approval under the Hatch-Waxman Act. [1]

What patents protected Farxiga in the Teva litigation?

The early Farxiga patent estate centered on patents covering dapagliflozin and related C-glucoside compounds. Public Orange Book records identify U.S. Patent Nos. 6,414,126 and 6,515,117 among the foundational Farxiga patents. [2]

Principal Farxiga patent categories

Patent category	Protected subject matter	Commercial relevance
Compound patents	Dapagliflozin and related C-glucoside compounds	Primary barrier to early generic entry
Pharmaceutical composition patents	Dapagliflozin formulations and tablet compositions	Product-specific protection
Manufacturing patents	Processes for preparing dapagliflozin and intermediates	May restrict non-infringing manufacturing routes
Method-of-use patents	Treatment of diabetes and later cardiovascular or renal conditions	Relevant to skinny-label and full-label entry
Formulation patents	Tablet and solid-form attributes	Can extend protection beyond core compound claims

The precise claims asserted against Teva must be distinguished from the broader Orange Book listing. A listed patent is not necessarily asserted in every ANDA case. Hatch-Waxman complaints typically identify the patents implicated by the defendant's certification, while later amendments may add or remove asserted patents.

When did Farxiga patents expire?

The principal compound patents had expiration dates in the early 2020s, subject to patent-term adjustment, patent-term extension, and pediatric exclusivity calculations. Later patents covering formulations, crystalline forms, combinations, and newer indications extended portions of the Farxiga estate beyond the foundational patents.

Farxiga exclusivity timeline

Date or period	Event
2001	Foundational dapagliflozin patent family filings
2014	FDA approval of Farxiga in the United States
2014	AstraZeneca filed ANDA litigation against Teva
2014-2017	Early Farxiga patent litigation and settlement activity
2020-2021	Expiration period for important foundational patent rights, subject to adjustments
2020s	Additional patents covered formulations, combinations, and later indications
2025 and later	Generic entry became dependent on remaining patent rights, FDA review, and settlement restrictions

The expiration date of a patent family should not be treated as a single commercial launch date. A generic applicant may be blocked by a later-expiring Orange Book patent, a settlement restriction, pediatric exclusivity, a court injunction, or a separate patent covering the approved labeling.

What was Teva's Paragraph IV challenge?

Teva challenged AstraZeneca's Farxiga patent protection through a Paragraph IV certification in its ANDA filing. The certification represented that the relevant patents were invalid, unenforceable, or would not be infringed by Teva's proposed dapagliflozin product.

A Paragraph IV challenge creates two separate questions:

1. Whether Teva could prove that the asserted patents were invalid or not infringed.
2. Whether AstraZeneca could maintain a legally enforceable barrier through the 30-month stay, preliminary relief, settlement, or later patent litigation.

The filing did not authorize Teva to launch immediately. It created the statutory litigation framework and required AstraZeneca to sue within the statutory period if it wanted to preserve the automatic stay.

What was the procedural history of Case No. 1:14-cv-01478?

AstraZeneca filed the action in the District of Delaware after receiving Teva's Paragraph IV notice. The case was assigned Case No. 1:14-cv-01478. As in other Hatch-Waxman proceedings, the action involved pleadings, patent disclosures, claim-construction preparation, discovery, and settlement discussions.

The publicly reported outcome was a negotiated resolution rather than a final trial judgment on the validity of the asserted patents. The case was later dismissed pursuant to the parties' resolution. A dismissal based on settlement does not establish that the patents were valid, infringed, or enforceable. It establishes that the parties ended the specific dispute under contractual terms.

Did AstraZeneca and Teva settle the Farxiga patent litigation?

Yes. AstraZeneca and Teva resolved the dispute without a reported final merits determination. The commercial terms of Hatch-Waxman settlements are often confidential, although parties may disclose an authorized generic arrangement, launch date, license date, or other material consideration when required by securities law.

The practical effect of the settlement was to replace litigation uncertainty with a negotiated generic-entry framework. The settlement likely addressed at least the following commercial issues:

• Teva's earliest permitted launch date;
• the scope of any license to AstraZeneca's patent estate;
• treatment of later-issued or later-listed patents;
• potential authorized-generic rights;
• release and dismissal provisions; and
• allocation of risk if additional patents became relevant.

A settlement does not eliminate later litigation. AstraZeneca could bring a separate action over a later-issued patent, a different dosage form, a new indication, or conduct outside the settlement license.

What is the Orange Book status of Farxiga?

Farxiga's Orange Book position consists of multiple patent listings rather than a single blocking patent. The FDA Orange Book identifies patents and regulatory exclusivities submitted by the NDA holder. It does not decide patent validity or infringement. [2]

Orange Book considerations

A generic applicant evaluating Farxiga must assess:

• whether the ANDA includes Paragraph IV certifications;
• whether a listed patent covers the active ingredient, formulation, method of use, or product;
• whether the applicant can use a section viii statement to omit a patented indication;
• whether the generic label would induce infringement;
• whether the 30-month stay remains in effect;
• whether the patent has pediatric exclusivity;
• whether a later-issued patent creates a second litigation window; and
• whether a settlement license authorizes launch despite an unexpired patent.

Method-of-use patents are particularly important for Farxiga because the product's labeling expanded after its original diabetes approval. A generic applicant may attempt a skinny-label strategy by omitting a patented indication. That approach does not eliminate risk if the remaining label, promotional activity, or prescribing environment supports an induced-infringement claim.

What formulation patents and manufacturing patents affect generic Farxiga?

Farxiga generic-entry analysis cannot rely only on the original compound patents. Dapagliflozin products may also be protected by patents covering solid forms, tablet compositions, processes, and combinations with other diabetes medicines.

Formulation and manufacturing barriers

Formulation patents may cover:

• tablet excipient combinations;
• dissolution characteristics;
• particle size or crystalline form;
• stability profiles;
• dosage strengths; and
• manufacturing parameters.

Manufacturing patents may cover:

• protected intermediates;
• stereoselective synthesis;
• purification procedures;
• crystallization steps; and
• conversion to the marketed dapagliflozin form.

A non-infringing manufacturing route can reduce process-patent exposure, but it does not avoid compound or formulation claims. Conversely, a process patent may have limited commercial effect if the generic manufacturer can source the active pharmaceutical ingredient from a supplier using a different process.

How strong was AstraZeneca's Farxiga patent estate?

The estate was commercially strong during the early generic-challenge period because it combined foundational compound protection with regulatory exclusivity and a growing portfolio of follow-on patents. Its strength declined as the foundational patents approached expiration and generic applicants developed alternative claim-construction and invalidity arguments.

Strength assessment

Factor	Assessment
Core compound coverage	Strong during the principal patent term
Patent breadth	Broad early coverage, narrower for later follow-on patents
Regulatory position	Strong initial protection because Farxiga had no approved generic substitute
Formulation protection	Potentially meaningful, but dependent on claim scope and product overlap
Method-of-use protection	Increasingly important after later cardiovascular and renal approvals
Litigation outcome	No reported final invalidity judgment in the Teva case
Settlement leverage	High enough to produce resolution before a reported trial decision
Long-term durability	Reduced as foundational patents expired and later patents faced separate challenges

The settlement itself is not evidence that AstraZeneca would have won at trial. It is evidence that both sides assigned value to avoiding the cost, delay, and uncertainty of continued litigation.

Which companies challenged Farxiga exclusivity?

Teva was one of several generic-drug companies pursuing dapagliflozin approval or evaluating the Farxiga patent estate. Competitive challengers in an ANDA market may include large generic manufacturers, specialty generic companies, and companies filing through affiliates or licensing arrangements.

The commercial significance of the first successful challenger is substantial. The first approved generic may receive 180-day generic drug exclusivity if statutory conditions are satisfied. Later entrants face a different economics profile because price erosion accelerates after multiple approvals.

What generic launch risks existed after settlement?

The principal launch scenarios were:

1. Licensed early entry. Teva launches on the settlement date before full expiration of every Farxiga patent.
2. Patent-expiry entry. Teva waits until the relevant blocking patent expires.
3. Delayed approval. FDA approval is delayed by the 30-month stay or unresolved regulatory deficiencies.
4. Skinny-label entry. Teva launches with one or more patented indications omitted.
5. Follow-on litigation. AstraZeneca asserts later-issued patents against the approved product or label.
6. Multi-source erosion. Several generic approvals enter near the same date, reducing first-mover economics.

The most material risk for AstraZeneca was not limited to Teva's launch. Once one generic obtains approval, other ANDA applicants can use the litigation outcome, settlement framework, and claim analysis to accelerate their own entry strategies.

How did the case affect AstraZeneca's revenue exposure?

Farxiga became a major AstraZeneca growth product, with revenue driven by expansion from diabetes into heart failure and chronic kidney disease. That expansion increased the value of later method-of-use patents and reduced the importance of the original diabetes-only market.

Generic entry would affect:

• U.S. Farxiga net sales;
• pricing and rebate levels;
• formulary positioning;
• prescriptions for diabetes and cardiovascular uses;
• fixed-dose combination products; and
• the valuation of related dapagliflozin intellectual property.

The timing of generic entry is more important than the mere existence of a Paragraph IV challenge. A settlement that delays launch can preserve substantial branded revenue even without a merits judgment.

What is the current legal significance of AstraZeneca v. Teva?

The case is closed as a discrete Delaware litigation. It remains relevant for assessing Farxiga's early U.S. patent strategy, the commercial value of Paragraph IV litigation, and the way settlements manage generic-entry timing.

The case should not be used as authority for patent validity because it did not produce a reported final merits decision. Its primary value is commercial and procedural: it documents a challenge to AstraZeneca's Farxiga patent estate and the resolution of that challenge through settlement rather than trial.

Key Takeaways

• Case No. 1:14-cv-01478 was an ANDA patent action concerning AstraZeneca's Farxiga product.
• Teva challenged AstraZeneca's dapagliflozin patent protection through a Paragraph IV certification.
• The case was resolved by settlement and dismissal rather than a reported final judgment on validity or infringement.
• Farxiga protection included compound, formulation, manufacturing, and method-of-use patents.
• Orange Book listings do not determine patent validity and must be analyzed patent by patent.
• Later cardiovascular and renal indications increased the commercial value of AstraZeneca's follow-on patent estate.
• Generic launch timing depended on the settlement, remaining Orange Book patents, FDA approval, and any later litigation.

FAQs

What was the drug in AstraZeneca Pharmaceuticals LP v. Teva?

The case concerned Farxiga, AstraZeneca's dapagliflozin tablet product.

Did Teva win the Farxiga patent case?

There was no reported final merits judgment awarding Teva victory. The parties resolved the litigation through settlement.

Did the case invalidate AstraZeneca's Farxiga patents?

No reported decision in the case invalidated the asserted Farxiga patents. The dismissal reflected settlement, not a judicial ruling on patent validity.

Can a generic launch after a Farxiga patent settlement?

Yes. A settlement may grant a licensed launch date before all listed patents expire, subject to the settlement's terms and FDA approval.

Do Farxiga method-of-use patents block all generic dapagliflozin sales?

Not necessarily. A generic applicant may omit patented indications through a section viii statement, but the remaining label and commercialization conduct must avoid infringement risk.

References

1. U.S. Food and Drug Administration. (2024). Abbreviated new drug application approvals and Paragraph IV certifications. https://www.fda.gov

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. District Court for the District of Delaware. (2014). AstraZeneca Pharmaceuticals LP v. Teva Pharmaceuticals USA Inc., No. 1:14-cv-01478.

4. U.S. Patent and Trademark Office. (2024). Patent term adjustment and patent term extension information. https://www.uspto.gov

5. AstraZeneca PLC. (2024). Annual report and Form 20-F. https://www.astrazeneca.com/investor-relations.html